Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.26 is 171% above its 2-year average of -0.37, near the high end of its 2-year range (-4.14–0.26).
As of the fiscal period ended Tuesday, June 30, 2026. 126.09% above its 12-month average of 0.12.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.26.
DEBT TO EQUITY RATIO
0.26
DEBT TO EQUITY RATIO AVG TTM
0.12
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+126.09%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
+85.82%
vs the sector median at left
Market Cap
$409.83M
Debt to Equity Ratio
0.54
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$405.95M
Debt to Equity Ratio
0.12
TTM Avg
0.11
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$404.94M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$410.44M
Debt to Equity Ratio
0.69
TTM Avg
0.39
3Y Avg
0.28
5Y Avg
0.26
Market Cap
$377.74M
Debt to Equity Ratio
0.13
TTM Avg
0.12
3Y Avg
0.17
5Y Avg
0.17
Market Cap
$424.32M
Debt to Equity Ratio
0.15
TTM Avg
1.54
3Y Avg
0.83
5Y Avg
0.58
Market Cap
$432.48M
Debt to Equity Ratio
0.37
TTM Avg
0.04
3Y Avg
0.21
5Y Avg
0.20
Market Cap
$434.00M
Debt to Equity Ratio
0.01
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $406.96M | 0.26 | 0.12 | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $409.83M | 0.54 | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $405.95M | 0.12 | 0.11 | 0.11 | 0.11 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $404.94M | 0.00 | 0.00 | 0.00 | 0.00 |
| Myriad Genetics, Inc. (MYGN)vs › | $410.44M | 0.69 | 0.39 | 0.28 | 0.26 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $377.74M | 0.13 | 0.12 | 0.17 | 0.17 |
| Editas Medicine, Inc. (EDIT)vs › | $424.32M | 0.15 | 1.54 | 0.83 | 0.58 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.48M | 0.37 | 0.04 | 0.21 | 0.20 |
| Assembly Biosciences, Inc. (ASMB)vs › | $434.00M | 0.01 | 0.05 | 0.05 | 0.05 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $382.35M | 0.01 | 0.03 | 0.11 | 0.11 |
Debt/Equity
0.26
Current Ratio
8.84
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.26 |
| 2026-03-31 | 0.19 |
| 2025-12-31 | 0.18 |
| 2025-09-30 | 0.17 |
| 2025-06-30 | -0.21 |
| 2025-03-31 | -0.22 |
| 2024-12-31 | -0.24 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | -4.14 |
